Finally, CD160+ CD8 T cells have been shown to express higher PD-1 levels than the CD160− counterpart, to have less proliferative and cytotoxic potential and to be enriched among CD8 TILs in pancreatic cancer patients (69). This evidence concerns the gene CD8A and familial pancreatic carcinoma.